
By BY MARC SANTORA AND CORA ENGELBRECHT from NYT Health https://ift.tt/3a3UK95
The drug maker claims clinical trials of its new antiviral pill molnupiravir shows the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19.